Bullous Keratopathy — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Bullous keratopathy is characterized by corneal stromal edema and the formation of epithelial or subepithelial bullae resulting from cell loss and endothelial decompensation. In more advanced stages, additional features such as subepithelial fibrosis, the development of a posterior collagenous layer (or retrocorneal fibrous membrane), and corneal vascularization may manifest. The condition leads to decreased vision due to the loss of corneal transparency, with accompanying symptoms like tearing and pain arising from ruptured epithelial bullae. Bullous keratopathy is the most prevalent indication for penetrating keratoplasty and regraft procedures. The primary cause of this condition is the loss of endothelial cells, particularly following ophthalmic surgeries such as cataract surgery.
Thelansis’s “Bullous Keratopathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bullous Keratopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Bullous Keratopathy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Bullous Keratopathy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
